Full Press Release Details
lynozyfic linvoseltamab approved in the european union for the treatment of relapsed refractory multiple myeloma.
REGN
lynozyfic linvoseltamab approved in the european union for the treatment of relapsed refractory multiple myeloma
Key Takeaway: lynozyfic linvoseltamab approved in the european union for the treatment of relapsed refractory multiple myeloma